Thomas Devlin, MD

Financial relationships

  • Type of financial relationship: 
    Employment
    Ineligible company: 
    Neuroscience Innovation Foundation
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Nova Signal
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Viz.ai
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Medtronic
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Speakers Bureau for Viz.ai
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Board of Directors, Neuroscience Innovation Foundation
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Stock
    Ineligible company: 
    Viz.ai
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Stock
    Ineligible company: 
    Nova Signal
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Viz.ai
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Nova Signal
    Date added: 
    03/30/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    02/29/2024

Pages

Return to Challenging Stroke Cases Panel Discussion - Enduring